CRCA · ARCA · ETF
ProShares Ultra CRCL (CRCA) Price, Holdings & Fees
ProShares Ultra CRCL (CRCA) closed at $607.19 on Oct 9, 2026, down 0.32% from the previous close of $609.12.
Share price, past year
1Y +20.05%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $607.19 |
| Sep 30, 2026 | $596.00 |
| Aug 31, 2026 | $577.90 |
| Jul 31, 2026 | $570.22 |
| Jun 30, 2026 | $547.72 |
| May 29, 2026 | $498.39 |
| Apr 30, 2026 | $481.12 |
| Mar 31, 2026 | $477.57 |
| Feb 27, 2026 | $478.12 |
| Jan 30, 2026 | $470.27 |
| Dec 31, 2025 | $488.07 |
| Nov 28, 2025 | $501.76 |
| Oct 31, 2025 | $495.55 |
Key statistics
- Expense ratio
- 0.95%
- as of May 31, 2025
- Net assets
- $227.5M
- as of May 31, 2026
- Holdings
- 11
- as of May 31, 2026
- 52-week range
- $454.52 – $609.12
ProShares Ultra CRCL's expense ratio is 0.95%: $95.00 a year on $10,000 invested.
Holdings
ProShares Ultra CRCL held 11 investments worth $227.54M as of May 31, 2026. Its largest holding was Repurchase Agreement, at 6.18% of the fund.
| # | Holding | % of fund | Value |
|---|---|---|---|
| 1 | Repurchase Agreement | 6.18% | $14.06M |
| 2 | N/A | 4.32% | $9.83M |
| 3 | Repurchase Agreement | 3.89% | $8.85M |
| 4 | Repurchase Agreement | 2.92% | $6.63M |
| 5 | Repurchase Agreement | 2.14% | $4.86M |
| 6 | N/A | 0.21% | $466.75K |
| 7 | N/A | −2.27% | −$5.17M |
| 8 | N/A | −2.52% | −$5.73M |
| 9 | N/A | −2.98% | −$6.79M |
| 10 | N/A | −3.09% | −$7.04M |
| 11 | N/A | −4.42% | −$10.05M |
Top 11 of 11 holdings, as of May 31, 2026. Percentages are of the fund's net assets.
What the fund owns
| Asset type | % of fund |
|---|---|
| Repurchase agreements | 15.12% |
| Derivatives | −10.76% |
| Country | % of fund |
|---|---|
| United States | 4.36% |
Shares of net assets from the fund's N-PORT report. Funds that borrow can add up to more than 100%, with borrowing (such as repurchase agreements) shown as a negative share.
Monthly total returns
Over the 3 months to May 31, 2026, ProShares Ultra CRCL's total return was +31.78%, as reported to the SEC.
| Month | Total return |
|---|---|
| May 31, 2026 | +38.29% |
| Apr 30, 2026 | −16.00% |
| Mar 31, 2026 | +13.44% |
The fund's own total returns as reported to the SEC (N-PORT), including reinvested distributions. Not the sample prices above.
Fund profile
- Name
- ProShares Ultra CRCL
- Ticker
- CRCA
- Exchange
- ARCA
- Fund type
- ETF
- Trust
- PROSHARES TRUST
- SEC series ID
- S000094784
- SEC CIK
- 0001174610
- Fractional shares
- Yes
Recent SEC filings
- Jul 28, 2026
- 485BPOSProspectus updateSep 25, 2026
- Aug 6, 2026
- 485BPOSProspectus updateJul 23, 2026
- 485BPOSProspectus updateJul 15, 2026
- 485BPOSProspectus updateJul 2, 2026
- 485BPOSProspectus updateJun 8, 2026
- 485BPOSProspectus updateMay 1, 2026
Shareholder reports and prospectuses are filed by PROSHARES TRUST, the trust behind ProShares Ultra CRCL, and cover all of its funds.
Frequently asked questions
What is CRCA's price?
ProShares Ultra CRCL (CRCA) closed at $607.19 on Oct 9, 2026, down 0.32% from the previous close of $609.12.
What is CRCA's expense ratio?
ProShares Ultra CRCL's expense ratio is 0.95%: $95.00 a year on $10,000 invested.
What does CRCA hold?
ProShares Ultra CRCL held 11 investments worth $227.54M as of May 31, 2026. Its largest holding was Repurchase Agreement, at 6.18% of the fund. Its five largest holdings were Repurchase Agreement, N/A, Repurchase Agreement, Repurchase Agreement, Repurchase Agreement.
How has CRCA performed?
Over the 3 months to May 31, 2026, ProShares Ultra CRCL's total return was +31.78%, as reported to the SEC.
Sources and methodology
Holdings, net assets and monthly returns come from the fund's N-PORT filing with the SEC, as of May 31, 2026 (filed Jul 28, 2026). The expense ratio is from the fund's prospectus or shareholder report, as of May 31, 2025. Prices are generated sample data for development. Data sources and disclosures